* known history of sars-cov-2 infection within 2 weeks prior to administration of vaccine or known close contact with anyone with laboratory-confirmed sars-cov-2 infection or covid-19 within 2 weeks prior to administration of vaccine. * prior administration of an investigational or approved cov (such as, sars-cov-2, sars cov, middle east respiratory syndrome cov) vaccine. * treatment with investigational or approved agents for prophylaxis against covid 19 (such as, receipt of sars-cov-2 monoclonal antibodies) within 6 months prior to enrollment. * known hypersensitivity to a component of the vaccine or its excipients. * a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. * history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. * received any non-study vaccine within 14 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) * received intravenous or subcutaneous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to day 1 * participated in an interventional clinical study within 28 days prior to day 0 or plans to donate blood products while participating in this study.

* known history of sars-cov-2 infection within 2 weeks prior to administration of vaccine or known close contact with anyone with laboratory-confirmed sars-cov-2 infection or covid-19 within 2 weeks prior to administration of vaccine. * prior administration of an investigational or approved cov (such as, sars-cov-2, sars cov, middle east respiratory syndrome cov) vaccine. * treatment with investigational or approved agents for prophylaxis against covid 19 (such as, receipt of sars-cov-2 monoclonal antibodies) within 6 months prior to enrollment. * known hypersensitivity to a component of the vaccine or its excipients. * a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. * history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. * received any non-study vaccine within 14 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) * received intravenous or subcutaneous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to day 1 * participated in an interventional clinical study within 28 days prior to day 0 or plans to donate blood products while participating in this study.

- known history of sars-cov-2 infection within 2 weeks prior to administration of vaccine or known close contact with anyone with laboratory-confirmed sars-cov-2 infection or covid-19 within 2 weeks prior to administration of vaccine. - prior administration of an investigational or approved cov (such as, sars-cov-2, sars cov, middle east respiratory syndrome cov) vaccine. - treatment with investigational or approved agents for prophylaxis against covid 19 (such as, receipt of sars-cov-2 monoclonal antibodies) within 6 months prior to enrollment. - known hypersensitivity to a component of the vaccine or its excipients. - a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. - history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. - received any non-study vaccine within 14 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) - received intravenous or subcutaneous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to day 1 - participated in an interventional clinical study within 28 days prior to day 0 or plans to donate blood products while participating in this study.

- known history of sars-cov-2 infection within 2 weeks prior to administration of vaccine or known close contact with anyone with laboratory-confirmed sars-cov-2 infection or covid-19 within 2 weeks prior to administration of vaccine. - prior administration of an investigational or approved cov (such as, sars-cov-2, sars cov, middle east respiratory syndrome cov) vaccine. - treatment with investigational or approved agents for prophylaxis against covid 19 (such as, receipt of sars-cov-2 monoclonal antibodies) within 6 months prior to enrollment. - known hypersensitivity to a component of the vaccine or its excipients. - a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. - history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. - received any non-study vaccine within 14 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) - received intravenous or subcutaneous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to day 1 - participated in an interventional clinical study within 28 days prior to day 0 or plans to donate blood products while participating in this study.

- known history of sars-cov-2 infection within 2 weeks prior to administration of vaccine or known close contact with anyone with laboratory-confirmed sars-cov-2 infection or covid-19 within 2 weeks prior to administration of vaccine. - prior administration of an investigational or approved cov (such as, sars-cov-2, sars cov, middle east respiratory syndrome cov) vaccine. - treatment with investigational or approved agents for prophylaxis against covid 19 (such as, receipt of sars-cov-2 monoclonal antibodies) within 6 months prior to enrollment. - known hypersensitivity to a component of the vaccine or its excipients. - a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. - history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. - received any non-study vaccine within 14 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) - received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to day 1 - participated in an interventional clinical study within 28 days prior to day 0 or plans to donate blood products while participating in this study.

- known history of sars-cov-2 infection within 2 weeks prior to administration of vaccine or known close contact with anyone with laboratory-confirmed sars-cov-2 infection or covid-19 within 2 weeks prior to administration of vaccine. - prior administration of an investigational or approved cov (such as, sars-cov-2, sars cov, middle east respiratory syndrome cov) vaccine. - treatment with investigational or approved agents for prophylaxis against covid 19 (such as, receipt of sars-cov-2 monoclonal antibodies) within 6 months prior to enrollment. - known hypersensitivity to a component of the vaccine or its excipients. - a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. - history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety. - received any non-study vaccine within 14 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine) - received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to day 1 - participated in an interventional clinical study within 28 days prior to day 0 or plans to donate blood products while participating in this study.